Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases)

Arnesano, 2021, Interference between copper transport systems and platinum drugs, Semin Cancer Biol., 76, 173, 10.1016/j.semcancer.2021.05.023 Barr, 2013, Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature, PLoS ONE, 8, 10.1371/journal.pone.0054193 Bukowski, 2020, Mechanisms of multidrug resistance in cancer chemotherapy, Int. J. Mol. Sci., 21, 3233, 10.3390/ijms21093233 Burkhead, 2009, Copper homeostasis, New Phytol., 182, 799, 10.1111/j.1469-8137.2009.02846.x Chen, 2015, Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy, Expert Opin. Ther. Targets, 19, 1307, 10.1517/14728222.2015.1043269 Denoyer, 2015, Targeting copper in cancer therapy: “copper that cancer”, Metallomics, 7, 1459, 10.1039/C5MT00149H El Sayed, 2018, Inhibition of SRC/FAK cue: a novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma, Life Sci., 213, 248, 10.1016/j.lfs.2018.10.002 Fang, 2018, Differential reactivity of metal binding domains ofcopper ATPases towards cisplatin and colocalization of copper and platinum, Chem. Eur. J., 24, 8999, 10.1002/chem.201801894 Gaetke, 2014, Copper: toxicological relevance and mechanisms, Arch. Toxicol., 88, 1929, 10.1007/s00204-014-1355-y Galanski, 2008, Recent developments in the field of anticancer platinum complexes, Recent Pat. Anticancer Drug Discov., 1, 285, 10.2174/157489206777442287 Grubman, 2014, Copper as a key regulator of cell signalling pathways, Expert Rev. Mol. Med., 16, 10.1017/erm.2014.11 Hirai, 2010, MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo, Mol. Cancer Ther., 9, 1956, 10.1158/1535-7163.MCT-09-1012 Inesi, 2017, Molecular features of copper binding proteins involved in copper homeostasis, IUBMB Life, 69, 211, 10.1002/iub.1590 Islam, 2020, A typical protein kinase-C inhibitors exhibit a synergistic effect in facilitating DNA damaging effect of 5-fluorouracil in colorectal cancer cells, Biomed. Pharmacother., 121 Kalayda, 2008, Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells, BMC Cancer, 8, 175, 10.1186/1471-2407-8-175 Katano, 2003, The copper export pump ATP7B modulates the cellular pharmacology of Carboplatin in ovarian carcinoma cells, Mol. Pharmacol., 64, 466, 10.1124/mol.64.2.466 Kim, 2008, Mechanisms for copper acquisition, distribution and regulation, Nat. Chem. Biol., 4, 176, 10.1038/nchembio.72 Kuo, 2007, The roles of copper transporters in cisplatin resistance, Cancer Metastasis Rev., 26, 71, 10.1007/s10555-007-9045-3 La Fontaine, 2010, Mammalian copper-transporting P-type ATPases, ATP7A and ATP7B: emerging roles, Int. J. Biochem. Cell Biol., 42, 206, 10.1016/j.biocel.2009.11.007 Lasorsa, 2019, Mechanistic and structural basis for inhibition of copper trafficking by platinum anticancer drugs, J. Am. Chem. Soc., 141, 12109, 10.1021/jacs.9b05550 Lebwohl, 1998, Clinical development of platinum complexes in cancer therapy: an historical perspective and an update, Eur. J. Cancer, 34, 1522, 10.1016/S0959-8049(98)00224-X Li, 2018, Copper efflux transporters ATP7A and ATP7B: novel biomarkers for platinum drug resistance and targets for therapy, IUBMB Life, 70, 183, 10.1002/iub.1722 Liljedahl, 2001, Protein kinase D regulates the fission of cell surface destined transport carriers from the trans-Golgi network, Cell, 104, 409, 10.1016/S0092-8674(01)00228-8 Lutsenko, 2010, Human copper homeostasis: a network of interconnected pathways, Curr. Opin. Chem. Biol., 14, 211, 10.1016/j.cbpa.2010.01.003 Manto, 2014, Abnormal copper homeostasis: mechanisms and roles in neurodegeneration, Toxics, 2, 327, 10.3390/toxics2020327 Ozols, 2003, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J. Clin. Oncol., 21, 3194, 10.1200/JCO.2003.02.153 Pilankatta, 2011, Involvement of protein kinase D in expression and trafficking of ATP7B (Copper ATPase), J. Biol. Chem., 286, 7389, 10.1074/jbc.M110.171454 Prohaska, 2008, Role of copper transporters in copper homeostasis, Am. J. Clin. Nutr., 88, 826, 10.1093/ajcn/88.3.826S Safaei, 2008, Transport of Cisplatin by the copper efflux transporter ATP7B, Mol. Pharmacol., 73, 461, 10.1124/mol.107.040980 Safaei, 2012, The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin, J. Inorg. Biochem., 110, 8, 10.1016/j.jinorgbio.2012.02.016 Tadini-Buoninsegni, 2010, ATP dependent charge movement in ATP7B Cu + -ATPase is demonstrated by pre-steady state electrical measurements, FEBS Lett., 584, 4619, 10.1016/j.febslet.2010.10.029 Tadini-Buoninsegni, 2014, Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B, Angew. Chem., 53, 1297, 10.1002/anie.201307718 Tadini-Buoninsegni, 2017, Mechanisms of charge transfer in human copper ATPases ATP7A and ATP7B, IUBMB Life, 69, 218, 10.1002/iub.1603 Van Lint, 2002, Protein kinase D: an intracellular traffic regulator on the move, Trends Cell Biol., 12, 193, 10.1016/S0962-8924(02)02262-6 Wei, 2015, The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells, Oncotarget, 6, 4745, 10.18632/oncotarget.2938 Yamaguchi, 2011, Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo, Int. J. Oncol., 39, 23